Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University of Munich, Munich, Germany.
Nat Rev Nephrol. 2019 Nov;15(11):671-692. doi: 10.1038/s41581-019-0181-0. Epub 2019 Aug 27.
Intravascular haemolysis is a fundamental feature of chronic hereditary and acquired haemolytic anaemias, including those associated with haemoglobinopathies, complement disorders and infectious diseases such as malaria. Destabilization of red blood cells (RBCs) within the vasculature results in systemic inflammation, vasomotor dysfunction, thrombophilia and proliferative vasculopathy. The haemoprotein scavengers haptoglobin and haemopexin act to limit circulating levels of free haemoglobin, haem and iron - potentially toxic species that are released from injured RBCs. However, these adaptive defence systems can fail owing to ongoing intravascular disintegration of RBCs. Induction of the haem-degrading enzyme haem oxygenase 1 (HO1) - and potentially HO2 - represents a response to, and endogenous defence against, large amounts of cellular haem; however, this system can also become saturated. A frequent adverse consequence of massive and/or chronic haemolysis is kidney injury, which contributes to the morbidity and mortality of chronic haemolytic diseases. Intravascular destruction of RBCs and the resulting accumulation of haemoproteins can induce kidney injury via a number of mechanisms, including oxidative stress and cytotoxicity pathways, through the formation of intratubular casts and through direct as well as indirect proinflammatory effects, the latter via the activation of neutrophils and monocytes. Understanding of the detailed pathophysiology of haemolysis-induced kidney injury offers opportunities for the design and implementation of new therapeutic strategies to counteract the unfavourable and potentially fatal effects of haemolysis on the kidney.
血管内溶血是慢性遗传性和获得性溶血性贫血的一个基本特征,包括与血红蛋白病、补体紊乱和疟疾等传染病相关的贫血。血管内红细胞(RBC)的不稳定导致全身炎症、血管舒缩功能障碍、血栓形成倾向和增生性血管病变。血红蛋白结合蛋白和血红素结合蛋白等血红素蛋白清除剂可限制游离血红蛋白、血红素和铁的循环水平 - 这些是从受损 RBC 释放的潜在毒性物质。然而,由于 RBC 持续的血管内崩解,这些适应性防御系统可能会失效。诱导血红素降解酶血红素加氧酶 1(HO1)- 以及潜在的 HO2 - 是对大量细胞血红素的反应和内源性防御;然而,该系统也可能饱和。大量和/或慢性溶血的常见不良后果是肾损伤,这导致慢性溶血性疾病的发病率和死亡率增加。RBC 的血管内破坏以及由此产生的血红素蛋白的积累可以通过多种机制导致肾损伤,包括氧化应激和细胞毒性途径、通过形成管内铸型以及通过直接和间接的促炎作用,后者通过中性粒细胞和单核细胞的激活。对溶血性肾损伤的详细病理生理学的理解为设计和实施新的治疗策略提供了机会,以对抗溶血对肾脏的不利和潜在致命影响。